Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

Accropeutics said the Phase II trial of AC-201 will support the drugs progression to a Phase III trial in plaque psoriasis.

Member states of the World Health Organization (WHO) have recently agreed on the world's first Pandemic Agreement.

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

Queen's Health Sciences (QHS) in Canada has announced the launch of a centralised Clinical Trial Support Unit (CTSU).

Zura Bio has launched the Phase II TibuSHIELD trial of tibulizumab for moderate to severe hidradenitis suppurativa (HS).

Viridian Therapeutics’ veligrotug has shown one-year durability in a Phase III trial in patients with active thyroid eye ...

KaliVir Immunotherapeutics has concluded the first cohort in the Phase I/Ib STEALTH-001 trial evaluating VET3-TGI for ...